Vital Farms: Risks Are Mounting, But The 77% Crash Makes The Valuation Too Cheap To Ignore

Vital Farms (VITL) — Buy

Vital Farms gained 200 basis points of retail dollar share while its gross margin collapsed from 38.9% to 6.6% and the stock fell 61% year-to-date. That is the paradox at the center of the Q2 2026 report: the brand is winning share even as the business is hemorrhaging cash.

The question is whether the valuation reset — from over 10 times sales to 0.68 times — has moved past business deterioration, or whether the egg glut that destroyed margins has enough duration to make this a value trap.

What happened

Revenue of $166 million fell 10.1% year-over-year. On the surface that looks like a shrinking business. But the volume decline was partially masked by forced sales into low-margin breaker and wholesale channels. The real damage showed up in gross margin, which compressed 32 percentage points from 38.9% to 6.6%, dragging gross profit down from $71.8 million to $10.9 million.

The mechanism was straightforward. Industry-wide egg oversupply pushed shell egg category prices down more than 35% year-over-year. Vital Farms' premium-priced eggs became uncomfortably expensive relative to commodity competitors. The company responded by narrowing its price gap to branded rivals from $2.51 in Q1 to $2.36 in Q2, and by absorbing a massive volume of excess eggs into breaker and wholesale channels that sold at near-zero margin.

That breaker strategy cost $19.5 million in gross profit reduction plus $1.5 million in related shipping and distribution costs. Add $7.8 million to wind down the butter business, $0.8 million in farmer contract amendments, and $3 million in consulting fees for a feed cost program, and you get the $28.1 million in discrete supply-management expenses that management separated from core results.

The adjusted EBITDA — earnings before interest, taxes, depreciation, and amortization, a rough cash-earnings proxy that strips out non-cash and discrete costs — still shows a $26.6 million loss versus a $29.9 million profit a year earlier, because the $19.5 million in breaker costs wasn't added back. That makes Vital Farms' adjusted metrics less decorative than some consumer stalwarts' versions: the oversupply pain shows up in both GAAP and adjusted results.

The share gain matters

Here is the one bright line: retail dollar share of the shell egg category grew more than 200 basis points year-over-year, per Circana data. When commodity egg prices collapse, consumers looking for affordable protein shift away from the premium tier. Vital Farms moved in the opposite direction. Management pointed to a top retailer where household acquisition improved 27% since mid-April, when price gaps were narrowed.

The company also reported shell egg velocity — units per store per week per item — up 12.5% as of mid-July compared to the Q1 earnings call, the highest level since February. Distribution points are projected to reach 170-175 by Q4, up from 130 in 2025.

This isn't the kind of share gain that reverses a quarterly result, but it tells you the brand has staying power when you remove the commodity pricing distortion from the equation. The question isn't whether the brand is still credible. It's whether margins can recover without permanently sacrificing that premium positioning.

What management is doing

The supply-side fixes are operational, not aspirational. Farmer contract amendments have been executed to right-size production at the source, rather than relying on the expensive breaker strategy. Management states supply and demand are now in balance heading into Q3. Breaker costs are expected to fall meaningfully in H2, though some will remain through Q3 and Q4 to maintain flexibility.

On the cost side, organizational streamlining in May and July should reduce the SG&A run rate by $6-7 million on an annualized basis. Capex has been dialed back: the Vital Crossroads facility has been paused through end of fiscal 2026, and the remaining $80-90 million to complete it won't be committed until demand signals improve.

The butter business, which was supposed to be a second growth curve, is being wound down entirely. Management determined that converting remaining bulk inventory into retail product was uneconomical, so it's going to a melter instead. The $7.8 million exit cost is a one-time charge, and the distraction is removed.

The cash situation

This is where the picture gets tighter. Operating cash flow was negative $45.9 million over the first 26 weeks of fiscal 2026, versus $4.5 million provided in the prior-year period. Capital expenditures rose to $37.5 million in the same window, up from $10 million.

The company ended the quarter with $21.2 million in cash and has drawn $30 million on its previous revolving credit line. Post-quarter-end, Vital Farms secured $185 million in new credit facilities: a $125 million three-year term loan (fully drawn) and a $60 million asset-based lending facility. The share repurchase program, which had bought back $50 million worth of stock at an average of $13.29 per share, was terminated on August 3rd as a condition of the new lending terms.

The balance sheet isn't broken — debt-to-equity sits at 10.6% and the current ratio is 1.1x — but the liquidity cushion has thinned considerably from the debt-free position Vital Farms held not long ago. Inventory has swollen to $73.9 million from $66.5 million at year-end. That's the lingering oversupply working its way through the system.

Guidance is a floor, not a plan

Management reaffirmed full-year revenue of $775-$800 million and adjusted EBITDA of $0-$10 million. The revenue target assumes positive shell egg volume growth returns in H2 and no intensification of competitive activity. The EBITDA outlook includes a mid-$30 million hit from oversupply management costs and higher promotional spending.

The management team also indicated a 30% gross margin exit run rate as the target, down from the mid-30s range that characterized the business before the glut hit.

A $0-$10 million adjusted EBITDA range for the full year on nearly $800 million in revenue is effectively a breakeven business. That's what happens when a margin collapse and supply-management costs coincide. The fact that this guidance wasn't lowered further after a quarter as bad as Q2 tells you management sees the trough as being in the rearview mirror.

Valuation: the reset argument

At $12.51, Vital Farms trades at 0.68 times trailing sales, 6.5 times EV/EBITDA, and 8.0 times forward earnings. Market cap is $537 million, down from a 52-week high of $53.13 per share. This is a valuation that assumes the margin collapse is structural, not cyclical.

Compare that to Cal-Maine Foods, the largest branded egg producer, which trades at 1.37 times sales, 7.1 times EV/EBITDA, and 12.6 times earnings. Cal-Maine also pays a 3% dividend. Vital Farms is priced at less than half the sales multiple of its closest peer, even though the margin destruction came from a commodity cycle, not a broken business model.

If the company achieves its stated 30% gross margin run rate and the $6-7 million SG&A reduction takes hold, and H2 volume returns to growth, the business could deliver adjusted EBITDA well above the $10 million guidance ceiling. At that point, the 0.68 times sales multiple gets re-rated quickly because the market is pricing in permanent destruction.

The risk is the opposite scenario: oversupply lingers, the 35% category price decline compresses Vital Farms' price gap permanently, and the company settles into a low-margin existence at a lower multiple permanently. The butter business wind-down eliminates one potential offset. The capex pause means growth infrastructure is delayed.

The rating

I rate Vital Farms a Buy. This is a buy into pain, not a turnaround that's already working. The stock has fallen 77% from its 52-week high. The valuation has reset faster than the business has deteriorated. The brand is gaining share, not losing it. The supply-side fixes — farmer contracts, right-sized production, slowed capex — are operational, not aspirational. The gross margin collapse was driven by a commodity cycle disruption, not by a loss of pricing power or a broken brand.

The counterargument is real: commodity eggs at approximately $2 per dozen create a price gap that no amount of brand loyalty can fully bridge, and the consumer shift toward cheaper protein is structural. That pressure exists. But Vital Farms is gaining share, not losing it, while selling eggs at eight times the commodity price. If the brand were truly broken, the share gain wouldn't be there.

The catalyst clock is short. Q3 results in late October should show whether gross margins begin the climb back and whether volume growth returns. If margins stay in single digits into Q4, the cheap multiple is justified. If they move toward the 20-30% range, the 0.68 times sales multiple is a discount to a brand that survived a commodity crash and came out the other side with more retail share than it went in with.